Last updated on April 2019

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Brief description of study

This three-part study will be performed with participants on chronic hemodialysis.

  • Part A will assess plasma pharmacokinetics of DS2330a (free form of DS2330b) after a single dose of powder in bottle (PIB) or tablet formulations of DS2330b
  • Part B will test the safety, tolerability, and effects on serum phosphate (Pi) of 14-day repeated oral doses of DS-2330b PIB when given alone and when given along with sevelamer carbonate three times a day
  • Part C is optional, and will test the effects on serum phosphate (Pi) of 14-day repeated oral doses of DS-2330b tablets when given with sevelamer carbonate

After screening, participants should expect the study to last about 21 days for Part A, and 46 days for Parts B and C.

Clinical Study Identifier: NCT03305471

Contact Investigators or Research Sites near you

Start Over

DaVita Clinical Research

Lakewood, CO United States

Orlando Clinical Research Center

Orlando, FL United States

DaVita Clinical Research

Minneapolis, MN United States

Prism Clinical Research

Saint Paul, MN United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.